JP2013530937A5 - - Google Patents

Download PDF

Info

Publication number
JP2013530937A5
JP2013530937A5 JP2013508502A JP2013508502A JP2013530937A5 JP 2013530937 A5 JP2013530937 A5 JP 2013530937A5 JP 2013508502 A JP2013508502 A JP 2013508502A JP 2013508502 A JP2013508502 A JP 2013508502A JP 2013530937 A5 JP2013530937 A5 JP 2013530937A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
halogen
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013508502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/057203 external-priority patent/WO2011138393A1/en
Publication of JP2013530937A publication Critical patent/JP2013530937A/ja
Publication of JP2013530937A5 publication Critical patent/JP2013530937A5/ja
Pending legal-status Critical Current

Links

JP2013508502A 2010-05-06 2011-05-05 自己免疫疾患の処置剤 Pending JP2013530937A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06
EP10162079.7 2010-05-06
PCT/EP2011/057203 WO2011138393A1 (en) 2010-05-06 2011-05-05 Treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2013530937A JP2013530937A (ja) 2013-08-01
JP2013530937A5 true JP2013530937A5 (enExample) 2014-05-29

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013508502A Pending JP2013530937A (ja) 2010-05-06 2011-05-05 自己免疫疾患の処置剤

Country Status (24)

Country Link
US (1) US20130172297A1 (enExample)
EP (1) EP2566470A1 (enExample)
JP (1) JP2013530937A (enExample)
KR (1) KR20130066630A (enExample)
CN (1) CN102869353A (enExample)
AU (1) AU2011249784B2 (enExample)
BR (1) BR112012028190A2 (enExample)
CA (1) CA2795394A1 (enExample)
CL (1) CL2012003091A1 (enExample)
CR (1) CR20120566A (enExample)
CU (1) CU20120154A7 (enExample)
EA (1) EA201201514A1 (enExample)
EC (1) ECSP12012312A (enExample)
IL (1) IL222690A0 (enExample)
MA (1) MA34285B1 (enExample)
MX (1) MX2012012926A (enExample)
NZ (1) NZ603999A (enExample)
PE (1) PE20130612A1 (enExample)
PH (1) PH12012502418A1 (enExample)
SG (1) SG185746A1 (enExample)
TN (1) TN2012000509A1 (enExample)
TW (1) TW201201814A (enExample)
WO (1) WO2011138393A1 (enExample)
ZA (1) ZA201207710B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
WO2004074297A1 (ja) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
ES2351393T3 (es) * 2003-05-26 2011-02-03 Takeda Pharmaceutical Company Limited Sulfopirroles.
MXPA06002349A (es) 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
CN1918148B (zh) * 2004-02-11 2012-09-05 巴斯利尔药物股份公司 取代的苯并咪唑和它们诱导细胞凋亡的用途
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
CA2820510A1 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases

Similar Documents

Publication Publication Date Title
JP2014502641A5 (enExample)
JP2013508279A5 (enExample)
NZ593065A (en) Dosage regimen for a s1p receptor agonist
JP2010532768A5 (enExample)
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
JP2009542699A5 (enExample)
AR068986A1 (es) Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)
JP2009542702A5 (enExample)
RU2008146815A (ru) Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол т нестероидный противовоспалительный препарат
JP2011102304A5 (enExample)
JP2010522710A5 (enExample)
US20140011884A1 (en) Use of s1p receptor modulator
US10987365B2 (en) Compositions and methods for the treatment of pain
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
CN103027915A (zh) 氯喹治疗和氯丙嗪预防肺感染和损伤的用途
JP2015516419A5 (enExample)
JP2013530937A5 (enExample)
RU2008115613A (ru) Терапевтическое средство для лечения заболеваний печени, содержащее в качестве активного ингредиента производное 2-амино-1, 3-пропандиола, а также способ лечения заболеваний печени
JP2014511897A5 (enExample)
JP2013544794A5 (enExample)
JP2013525469A5 (enExample)
JP2005531612A (ja) ネフォパムの製剤および痛みの治療におけるその使用
RU2008113187A (ru) Лечение аутоиммунных заболеваний
RU2010147881A (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
RU2008108175A (ru) Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы